Cell Signaling Technology

Product Pathways - Protein Stability

Bortezomib #2204

Molecular Formula:
C19H25BN4O4
Molecular Weight:
384.24 g/mol
Purity:
99%

Directions for Use

Bortezomib is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 2.5 mg in 6.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-1000 nM for 2-48 hours. Soluble in DMSO and ethanol at 200 mg/ml, very poorly soluble in plain water.

Western Blotting

Western Blotting

Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated (+) with Bortezomib (100 nM, 6 hr), using Ubiquitin Antibody #3933 (left), p53 (1C12) Mouse mAb #2524 (middle), and β-Actin (13E5) Rabbit mAb #4970 (right).

Structure

Structure

Chemical structure of Bortezomib.

Western blot analysis of L363 cells, untreated (-) or treated (+) with Bortezomib (24 hr) as indicated, using K48-linkage Specific Polyubiquitin Antibody #4289.


Background

Bortezomib (C19H25BN4O4), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3).

  1. Williams, S.A. and McConkey, D.J. (2003) Cancer Res 63, 7338-44.
  2. Poulaki, V. et al. (2007) Invest Ophthalmol Vis Sci 48, 4706-19.
  3. Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

For Research Use Only. Not For Use In Diagnostic Procedures.

Products